Advisory Committee on Immunization Practices, 2619-2620 [2024-00674]
Download as PDF
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
Hepatitis, STD, and TB Prevention, Centers
for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–6, Atlanta,
Georgia 30329–4027. Telephone: (404) 718–
8833; Email: GAnderson@cdc.gov.
The Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, has been delegated the authority
to sign Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–00675 Filed 1–12–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2024–0001]
Advisory Committee on Immunization
Practices
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice and request for comment.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
Advisory Committee on Immunization
Practices (ACIP). This meeting is open
to the public. Time will be available for
public comment.
DATES: The meeting will be held on
February 28, 2024, from 8 a.m. to 5 p.m.,
EST and February 29, 2024, from 8 a.m.
to 3 p.m., EST, (times subject to change;
see the ACIP website for updates:
https://www.cdc.gov/vaccines/acip/
index.html).
Written comments must be received
between February 1–22, 2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0001, by either of the methods listed
below. CDC does not accept comments
by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Ms. Stephanie Thomas, ACIP
Meeting, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H24–8, Atlanta, Georgia
30329–4027. Attn: Docket No. CDC–
2024–0001.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
Instructions: All submissions received
must include the Agency name and
docket number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
The meeting will be webcast live via
the World Wide Web. The webcast link
can be found on the ACIP website at
https://www.cdc.gov/vaccines/acip/
index.html.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, Committee
Management Specialist, Advisory
Committee on Immunization Practices,
National Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–8,
Atlanta, Georgia 30329–4027.
Telephone: (404) 639–8836; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on
Immunization Practices (ACIP) is
charged with advising the Director,
Centers for Disease Control and
Prevention (CDC), on the use of
immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children program, along
with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under applicable provisions of the
Affordable Care Act and section 2713 of
the Public Health Service Act,
immunization recommendations of
ACIP that have been approved by the
Director, CDC, and appear on CDC
immunization schedules generally must
be covered by applicable health plans.
Matters To Be Considered: The agenda
will include discussions on influenza
vaccines, chikungunya vaccine, COVID–
19 vaccines, meningococcal vaccines,
pneumococcal vaccines, polio vaccines,
Human papillomavirus (HPV) vaccines,
respiratory syncytial virus vaccines, a
combined Diphtheria and Tetanus
Toxoids and Acellular Pertussis,
Inactivated Poliovirus, Haemophilus
influenzae Type B Conjugate, and
Hepatitis B vaccine (Vaxelis®), and
vaccines to prevent diphtheria, tetanus,
and pertussis. Recommendation votes
are scheduled for influenza vaccines,
COVID–19 vaccines, and chikungunya
vaccine. A Vaccines for Children (VFC)
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
2619
vote is scheduled for vaccines to
prevent diphtheria, tetanus, and
pertussis. Agenda items are subject to
change as priorities dictate. For more
information on the meeting agenda, visit
https://www.cdc.gov/vaccines/acip/
meetings/.
Meeting Information: The meeting
will be webcast live via the World Wide
Web. For more information on ACIP,
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near-duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on February 1–22, 2024.
Written comments must be received by
February 22, 2024.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes, including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the February 28–29,
2024, ACIP meeting must submit a
request at https://www.cdc.gov/
vaccines/acip/meetings/
between February 1, 2024, and no later
than 11:59 p.m., EST, February 22,
2024, according to the instructions
provided.
E:\FR\FM\16JAN1.SGM
16JAN1
2620
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by February 26, 2024. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to three minutes, and each
speaker may speak only once per
meeting.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–00674 Filed 1–12–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, National Center for Health
Statistics
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Board of
Scientific Counselors, National Center
for Health Statistics (BSC, NCHS). This
meeting is open to the public. Time will
be available for public comment.
DATES: The meeting will be held on
March 6, 2024, from 11 a.m. to 5 p.m.,
EST.
ADDRESSES: Instructions to access the
live meeting broadcast will be posted
here: https://www.cdc.gov/nchs/about/
bsc/bsc_meetings.htm.
FOR FURTHER INFORMATION CONTACT:
Rebecca Hines, M.H.S., Designated
Federal Officer, Board of Scientific
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
Counselors, National Center for Health
Statistics, Centers for Disease Control
and Prevention, 3311 Toledo Road,
Mailstop P–08, Hyattsville, Maryland
20782. Telephone: (301) 458–4715;
Email: RSHines@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board of Scientific
Counselors, National Center for Health
Statistics (BSC, NCHS) is charged with
providing advice and making
recommendations to the Secretary,
Department of Health and Human
Services; the Director, Centers for
Disease Control and Prevention; and the
Director, National Center for Health
Statistics, regarding the scientific and
technical program goals and objectives,
strategies, and priorities of NCHS.
Matters to be Considered: The
meeting agenda will include an update
from the NCHS Director; welcoming of
new Board members; updates from
NCHS programs; and discussion
regarding current issues and topics. The
Board will reserve time for public
comment at the end of the day. Meeting
times and agenda topics are subject to
change as priorities dictate.
Meeting Information: Please visit the
BSC, NCHS website for details: https://
www.cdc.gov/nchs/about/bsc/bsc_
meetings.htm. Further information and
the meeting agenda will be available on
the website, including any agenda
updates and the instructions for
accessing the live meeting broadcast.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–00641 Filed 1–12–24; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–1181; Docket No. CDC–2023–
0101]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Airline and
Traveler Information Collection:
Domestic Manifests and Passenger
Locator Form. These data collection
forms align with CDC’s regulatory and
public health mission under the
authorities listed in CDC regulations to
allow CDC to collect passenger and crew
information from travelers and airlines
when there has been a confirmed or
suspected case of communicable disease
aboard a domestic or international flight
that puts other travelers at public health
risk.
DATES: CDC must receive written
comments on or before March 18, 2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2023–
0101 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
SUMMARY:
E:\FR\FM\16JAN1.SGM
16JAN1
Agencies
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2619-2620]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00674]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2024-0001]
Advisory Committee on Immunization Practices
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with regulatory provisions, the Centers for
Disease Control and Prevention (CDC) announces the following meeting of
the Advisory Committee on Immunization Practices (ACIP). This meeting
is open to the public. Time will be available for public comment.
DATES: The meeting will be held on February 28, 2024, from 8 a.m. to 5
p.m., EST and February 29, 2024, from 8 a.m. to 3 p.m., EST, (times
subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/).
Written comments must be received between February 1-22, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0001, by either of the methods listed below. CDC does not accept
comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8,
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2024-0001.
Instructions: All submissions received must include the Agency name
and docket number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
The meeting will be webcast live via the World Wide Web. The
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management
Specialist, Advisory Committee on Immunization Practices, National
Center for Immunization and Respiratory Diseases, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta,
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on Immunization Practices (ACIP) is
charged with advising the Director, Centers for Disease Control and
Prevention (CDC), on the use of immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children program, along with schedules regarding dosing interval,
dosage, and contraindications to administration of vaccines. Further,
under applicable provisions of the Affordable Care Act and section 2713
of the Public Health Service Act, immunization recommendations of ACIP
that have been approved by the Director, CDC, and appear on CDC
immunization schedules generally must be covered by applicable health
plans.
Matters To Be Considered: The agenda will include discussions on
influenza vaccines, chikungunya vaccine, COVID-19 vaccines,
meningococcal vaccines, pneumococcal vaccines, polio vaccines, Human
papillomavirus (HPV) vaccines, respiratory syncytial virus vaccines, a
combined Diphtheria and Tetanus Toxoids and Acellular Pertussis,
Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and
Hepatitis B vaccine (Vaxelis[supreg]), and vaccines to prevent
diphtheria, tetanus, and pertussis. Recommendation votes are scheduled
for influenza vaccines, COVID-19 vaccines, and chikungunya vaccine. A
Vaccines for Children (VFC) vote is scheduled for vaccines to prevent
diphtheria, tetanus, and pertussis. Agenda items are subject to change
as priorities dictate. For more information on the meeting agenda,
visit https://www.cdc.gov/vaccines/acip/meetings/.
Meeting Information: The meeting will be webcast live via the World
Wide Web. For more information on ACIP, please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near-duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on February 1-22, 2024. Written comments must be
received by February 22, 2024.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes, including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the February 28-29, 2024, ACIP meeting must
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ between February 1, 2024, and no later than 11:59 p.m., EST,
February 22, 2024, according to the instructions provided.
[[Page 2620]]
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by February 26, 2024. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to three minutes, and each
speaker may speak only once per meeting.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-00674 Filed 1-12-24; 8:45 am]
BILLING CODE 4163-18-P